{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:50:43Z","timestamp":1790700643277,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973397"],"award-info":[{"award-number":["81973397"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2008301"],"award-info":[{"award-number":["2020YFC2008301"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cbi.2022.110123","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T01:37:01Z","timestamp":1661132221000},"page":"110123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline"],"prefix":"10.1016","volume":"366","author":[{"given":"Xiaoqin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhuan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanyong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhize","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5169-4696","authenticated-orcid":false,"given":"Jianchang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2022.110123_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/14656566.2012.643869","article-title":"Istradefylline for the treatment of Parkinson's disease","volume":"13","author":"Park","year":"2012","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.cbi.2022.110123_bib2","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1177\/0091270008320924","article-title":"A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin","volume":"48","author":"Rao","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110123_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14737175.2021.1880896","article-title":"Istradefylline - a first generation adenosine A(2A) antagonist for the treatment of Parkinson's disease","volume":"21","author":"Jenner","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.cbi.2022.110123_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/neurolint12030017","article-title":"Istradefylline to treat patients with Parkinson's disease experiencing \"off\" episodes: a comprehensive review","volume":"12","author":"Berger","year":"2020","journal-title":"Neurol. Int."},{"key":"10.1016\/j.cbi.2022.110123_bib5","first-page":"125","volume":"vol. 56","author":"Paton","year":"2020"},{"key":"10.1016\/j.cbi.2022.110123_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1517\/14740338.2015.1014798","article-title":"The safety of istradefylline for the treatment of Parkinson's disease","volume":"14","author":"M\u00fcller","year":"2015","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.cbi.2022.110123_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2012.08.030","article-title":"Istradefylline, an adenosine A\u2082A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis","volume":"324","author":"Chen","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.cbi.2022.110123_bib8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.2014.129","article-title":"Functional gene variants of CYP3A4","volume":"96","author":"Werk","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2022.110123_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/jcph.1003","article-title":"Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects","volume":"58","author":"Mukai","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110123_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drup.2008.03.002","article-title":"CYP450 pharmacogenetics for personalizing cancer therapy","volume":"11","author":"van Schaik","year":"2008","journal-title":"Drug Resist. Updates : Rev. Comment. Antimicrob. Anti Cancer Chemotherapy"},{"key":"10.1016\/j.cbi.2022.110123_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/pgs-2016-0179","article-title":"Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population","volume":"18","author":"Hu","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cbi.2022.110123_bib12","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1177\/0091270008328097","article-title":"Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin","volume":"49","author":"Srinivas","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110123_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/clc.23303","article-title":"Hypertension in older adults: assessment, management, and challenges","volume":"43","author":"Oliveros","year":"2020","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.cbi.2022.110123_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41531-021-00202-w","article-title":"Case-control study of hypertension and Parkinson's disease","volume":"7","author":"Ng","year":"2021","journal-title":"NPJ Parkinson's Dis."},{"key":"10.1016\/j.cbi.2022.110123_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78236-y","article-title":"Targeting continuity of care and polypharmacy to reduce drug-drug interaction","volume":"10","author":"Weng","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2022.110123_bib16","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.2147\/DDDT.S152366","article-title":"Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro","volume":"11","author":"Fang","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.cbi.2022.110123_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fphar.2019.00591","article-title":"Enzymatic activities of CYP3A4 allelic variants on quinine 3-hydroxylation in vitro","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110123_bib18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","article-title":"Parkinson disease: from pathology to molecular disease mechanisms","volume":"62","author":"Dexter","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.cbi.2022.110123_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1586\/14737175.2015.1113131","article-title":"The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease","volume":"15","author":"Vorovenci","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.cbi.2022.110123_bib20","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1021\/acsomega.0c05741","article-title":"Design, synthesis, and biological activity studies of istradefylline derivatives based on adenine as A(2A) receptor antagonists","volume":"6","author":"Wang","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.cbi.2022.110123_bib21","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1517\/17425255.2013.795541","article-title":"Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations","volume":"9","author":"M\u00fcller","year":"2013","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.cbi.2022.110123_bib22","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2217\/14622416.7.6.831","article-title":"Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population","volume":"7","author":"Du","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cbi.2022.110123_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/pgs.12.187","article-title":"CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy","volume":"14","author":"Elens","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cbi.2022.110123_bib24","first-page":"158","article-title":"Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects, Clinica chimica acta","volume":"383","author":"Ruzilawati","year":"2007","journal-title":"Int. J. Clin. Chem."},{"key":"10.1016\/j.cbi.2022.110123_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/jhg.2011.30","article-title":"Analysis of CYP3A4 genetic polymorphisms in Han Chinese","volume":"56","author":"Zhou","year":"2011","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.cbi.2022.110123_bib26","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1161\/01.CIR.103.9.1245","article-title":"Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study","volume":"103","author":"Franklin","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cbi.2022.110123_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11906-021-01146-5","article-title":"Management of hypertension and blood pressure dysregulation in patients with Parkinson's disease-a systematic review","volume":"23","author":"Katsi","year":"2021","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.cbi.2022.110123_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1573402115666191011111402","article-title":"Hospital working group on, resistant hypertension: novel insights","volume":"16","author":"Lamirault","year":"2020","journal-title":"Curr. Hypertens. Rev."},{"key":"10.1016\/j.cbi.2022.110123_bib29","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5692\/clinicalneurol.cn-000907","article-title":"[Posterior reversible encephalopathy syndrome in Parkinson disease probably caused by prominent supine hypertension and blood pressure fluctuation]","volume":"56","author":"Morozumi","year":"2016","journal-title":"Rinsho Shinkeigaku = Clin. Neurol."},{"key":"10.1016\/j.cbi.2022.110123_bib30","first-page":"744","article-title":"Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies, Clinical and experimental hypertension","volume":"30","author":"Tomassoni","year":"2008","journal-title":"New York, N.Y."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279722003283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279722003283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:12:56Z","timestamp":1757859176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279722003283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":30,"alternative-id":["S0009279722003283"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2022.110123","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2022.110123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110123"}}